https://www.ajmc.com/view/trastuzumab-deruxtecan-demonstrates-efficacy-reducing-brain-metastases-in-her2m-nsclc
0
0
10/22/23 at 8:23am
Organization
Ajmc.com
Regardless of presence of brain metastases, patients with HER2-mutant (HER2m) non–small cell lung cancer (NSCLC) showed systemic responses to trastuzumab deruxtecan. In addition, the therapy showed intracranial efficacy to reduce the size of brain metastases.
Create an account
or login to join the discussion